Oral arguments are set for January in the pharmaceutical industry's challenge of a 2-year-old Maine law aimed at reducing prescription-drug prices for low-income residents. The Pharmaceutical Research and Manufacturers of America filed a brief with the Supreme Court last week arguing that the Maine program violates Medicaid law and the commerce clause of the U.S. Constitution by regulating business transaction in other states. The state is expected to file its response within 30 days. Under the program, known as MaineRx, the state would negotiate rebates from drugmakers on behalf of residents without prescription-drug coverage and impose price controls if voluntary rebates are insufficient. The program has never been implemented because PhRMA obtained an injunction against it in October 2000, pending the result of its court challenge. The case is viewed as a possible bellwether for other states. -- by Jeff Tieman
Arguments set in High Court review of Maine law
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.